Aptamer Group
banner
aptamergroup.bsky.social
Aptamer Group
@aptamergroup.bsky.social
We develop Optimer® binders to enable innovation across research, diagnostics, therapeutics and bioprocessing.
We’ve levelled up! 🥇

🧬 Our ISO 9001 certification now covers synthesis, ensuring top quality across everything from internal development to custom aptamer and oligo synthesis. 🧬💎

Looking for synthesis support? We’ve got you. 🤝
October 9, 2025 at 10:19 AM
Hear what our customers are experiencing with Optimer technology.

⚡ Superior performance from day one
✅ Ready to use with minimal optimisation
🧬 Outperforming traditional antibodies

Ready to experience the Optimer advantage in your research? Get in touch to learn more.
October 3, 2025 at 8:22 AM
Technical update from Aptamer Group – Dr David Bunka shares the latest data & innovations. 6pm BST today. Register: turnerpope.com/register/
August 14, 2025 at 8:30 AM
Results of the General Meeting are now available.

To see the results, please head over to our Investor relations reports and presentation page.

aptamergroup.com/investors/re...
July 24, 2025 at 11:13 AM
The circular and information on the general meeting for shareholders, regarding the proposed placing of £2m, is available on our website: polaris.brighterir.com/public/aptam...
July 8, 2025 at 6:11 AM
We have successfully raised £2M. This will accelerate:
- Licensing discussions
- Manufacturing
- Biomarker discovery service launch
- Animal models for liver fibrosis delivery
- AI/ML integration into Optimer
polaris.brighterir.com/public/aptam...
July 4, 2025 at 6:08 AM
We've made great progress in the development of the Optimer delivery vehicle targeting liver fibrosis:
🔬 Identification of a novel biomarker targeted by Optimer for liver fibrosis therapies
🧬 Reduction in scar tissue formation in liver fibrosis models
👉 polaris.brighterir.com/public/aptam...
June 30, 2025 at 7:47 AM
Our new agreement with a global life science leader will see development of Optimer-Fc reagents for new immunohistochemistry reagents, with downstream licensing agreed.
Find out more here: polaris.brighterir.com/public/aptam...
June 25, 2025 at 6:08 AM
We're excited to announce the agreement of the second Optimer development programme with @unileveruki.bsky.social.

We look forward to working together to expand the potential of Optimer applications in personal care.

polaris.brighterir.com/public/aptam...
May 30, 2025 at 6:57 AM
Join us at this year's #BIO2025!

Our CEO, Arron Tolley, and CFO, Andrew Rapson, will be at this year’s BIO International Convention in Boston. Book a meeting to see how #Optimer can deliver better affinity ligands to support your pipeline.
letspartner.bio.org
May 29, 2025 at 8:16 AM
If you missed us at #ASGCT2025 last week, you can go to our website to download our poster, ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers: A Novel Approach for Fibrotic Liver Treatment’ which was presented at the conference.
go.aptamergroup.com/ASGCT-Poster
May 23, 2025 at 8:23 AM
We’re all set up and ready to go at #ASGCT.

Come meet our team at stand 714 to see how #Optimer, oligo-based antibody alternatives, can target gene therapy payloads to specific sites of action in the body or help build better assays for drug discovery and drug development.
May 13, 2025 at 2:51 PM
Join our team next week at #ASGCT to see how Optimer can help with:
🎯Targeted delivery for your gene therapy
🧪Custom reagents to build better assays
🔍 Identify new biomarkers of disease

Don’t miss our poster
📊 ‘Targeted Delivery of siRNA to Activated Hepatic Stellate Cells Using Aptamers’
May 9, 2025 at 11:38 AM
Meet us at #FoBUSA 📅 Apr 23–24, stand 1244! 🤝 Book time with Arron & Zeesharn + see poster 7 on Optimer® gene silencing in primary fibrotic hepatic stellate cells.
April 15, 2025 at 9:26 AM
Not all binders are equal. Learn how Optimer® binders are tailored for detection, purification & targeted delivery. Watch now: bit.ly/4bDGFwk
March 31, 2025 at 3:23 PM
Reproducibility matters. Chemically synthesized aptamers offer the highest batch consistency for robust assays & reliable data. 🔬📊

🔗 aptamergroup.com/aptamers-offer-the-highest-batch-consistency-for-reliable-reproducibility/
March 28, 2025 at 11:07 AM
📢 Our new knowledge centre is live! 🔍 Find the latest insights on Optimers for diagnostics, therapeutics & bioprocessing—now easier to search and explore. 🔬 Check it out: aptamergroup.com/knowledge-ce...
March 4, 2025 at 1:55 PM
Today is #RareDiseaseDay. 350M+ people are affected, yet finding reliable biomarkers remains a challenge. Better tools can drive progress. 💜
February 28, 2025 at 10:12 AM
ADCs are advancing precision medicine, though challenges persist. See how next-gen Optimer® binders enhance specificity, stability, and delivery for improved outcomes.

aptamergroup.com/expanding-ad...
February 21, 2025 at 10:19 AM
Wrapping up an inspiring California tour for our CEO, @ArronTolley! Arron engaged in productive discussions on how Optimer technology supports key projects. If you missed Arron or would like to learn more about how we can support your projects, please get in touch with our team.
February 19, 2025 at 9:15 AM
CEO Arron Tolley had a busy week in San Diego discussing #Optimer with current and potential partners, even the rain couldn't slow him. A quick trip to see the USS Midway before heading to San Francisco for more meetings!
February 14, 2025 at 9:20 AM
On Intl Women & Girls in Science Day, we honour women scientists & partners shaping life sciences. #InternationalWomenInScience #WomenInSTEM
February 11, 2025 at 11:01 AM
Our CEO, Arron Tolley, is in California this week. ✈️☀️👨‍🔬🧬

Book a meeting with him to find out more about Optimer or Optimer+ as targeted therapeutics, critical reagents or diagnostic tools.

calendly.com/arron-tolley...
February 10, 2025 at 11:25 AM
Looking for reagents to a new biomarker or simply want to upgrade your current antibody. Optimer binders are custom developed to meet your needs and help make you science unlimited.
February 3, 2025 at 11:20 AM
Today we have announced our half year results, showing significant commercial and technical progress with revenue growth. polaris.brighterir.com/public/aptam...
January 28, 2025 at 7:29 AM